SLB

SLB Intangible Assets

$4.88BQuarterly · USD

Period ending:

SLB FY Intangible AssetsUSD
SLB FY Intangible Assets1985-12-31: $534.30M1986-12-31: $118.00M1987-12-31: $231.10M1988-12-31: $243.20M1989-12-31: $274.40M1990-12-31: $401.40M1991-12-31: $439.50M1992-12-31: $564.40M1993-12-31: $1.11B1994-12-31: $1.20B1995-12-31: $1.33B1996-12-31: $0.001997-12-31: $0.001998-12-31: $0.001999-12-31: $0.002000-12-31: $0.002001-12-31: $7.07B2002-12-31: $4.79B2003-12-31: $3.69B2004-12-31: $3.14B2005-12-31: $542.04M2006-12-31: $907.87M2007-12-31: $902.70M2008-12-31: $819.99M2009-12-31: $288.00M2010-12-31: $5.16B2011-12-31: $4.88B2012-12-31: $4.80B2013-12-31: $4.71B2014-12-31: $4.65B2015-12-31: $4.57B2016-12-31: $9.86B2017-12-31: $9.35B2018-12-31: $8.73B2019-12-31: $7.09B2020-12-31: $3.46B2021-12-31: $3.21B2022-12-31: $2.99B2023-12-31: $3.24B2024-12-31: $3.01B2025-12-31: $4.99B$9.86B$0.00
1985-12-312025-12-31

Source: Financial Modeling Prep (FMP). Annual fiscal periods; reported in USD. Dates are period ends; a fiscal year may differ from a calendar year.

SLB intangible assets history

Patents, trademarks, and other intangible assets. The available annual fiscal periods series contains 41 observations from Dec 31, 1985 to Dec 31, 2025.

Schlumberger Intangible Assets — Annual fiscal periods (USD)
Period endingIntangible Assets (USD)
4,988,000,000
3,012,000,000
3,239,000,000
2,992,000,000
3,211,000,000
3,455,000,000
7,089,000,000
8,727,000,000
9,354,000,000
9,855,000,000
4,569,000,000
4,654,000,000
4,709,000,000
4,802,000,000
4,882,000,000
5,162,000,000
288,000,000
819,986,000
902,700,000
907,874,000
542,035,000
3,135,881,000
3,687,573,000
4,788,657,000
7,072,318,000
0
0
0
0
0
1,330,500,000
1,204,700,000
1,109,100,000
564,400,000
439,500,000
401,400,000
274,400,000
243,200,000
231,100,000
118,000,000
534,300,000

Compare intangible assets

All SLB financial metrics · SLB stock overview · How to interpret financial metrics

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.